Urgent air transfers for acute respiratory infections among children from Northern Canada, 2005–2014

Caitlin Prendergast, Joan Robinson, Chelsea Caya, Maria E. Perez Trejo, Iline Guan, Veronica Hébert-Murakami, Justina Marianayagam, Zing-Wae Wong, Celia Walker, David M. Goldfarb, Nick Barrowman, Radha Jetty, Joanne Embree, Veronica Hebert-Murakami, Justina Marianayagam, Zing-Wae Wong, Celia Walker, David M. Goldfarb, Nick Barrowman, Radha Jetty, Joanne Embree, Veronica Hebert-Murakami, Justina Marianayagam, Zing-Wae Wong, Celia Walker, David M. Goldfarb, Nick Barrowman, Radha Jetty, Joanne Embree

Abstract

Background
The incidence of hospitalizations for acute respiratory infections (ARI) among young Indigenous children from Northern Canada is consistently high. ARIs requiring urgent air transfer can be life-threatening and costly. We aimed to describe their epidemiology, estimate age-specific incidences, and explore factors associated with level of care required.

Methods
We undertook a retrospective cohort study of children <5 years old from Northern Canada transferred by urgent air transport for ARI from 2005 through 2014 to 5 pediatric tertiary care centers in Vancouver, Edmonton, Winnipeg, Ottawa and Montreal. Admissions were identified via ARI-related ICD-9/10 coding and forward sortation area. Descriptive statistics and univariable analyses were performed.

Results
Among 650 urgent air transfers, the majority were from Nunavut (n = 349, 53.7%) or Nunavik (n = 166, 25.5%), <6 months old (n = 372, 57.2%), and without underlying comorbidity (n = 458; 70.5%). Estimated annual tertiary care ARI admission rates in infants <1 year old from Nunavut (40.7/1000) and Nunavik (44.5/1000) were tenfold higher than in children aged 1 to 4 years. Bronchiolitis (n = 333, 51.2%) and pneumonia (n = 208, 32.0%) were the most common primary discharge diagnoses. Nearly half required critical care (n = 316, 48.6%); mechanical ventilation rates ranged from 7.2% to 55.9% across centres. The most common primary pathogen was respiratory syncytial virus (n = 196, 30.1%). Influenza A or B was
identified in 35 cases (5.4%) and vaccine-preventable bacterial infections in 27 (4.1%) cases.

**Interpretation**

Urgent air transfers for ARI from Northern Canada are associated with high acuity. Variations in levels of care were seen across referral centers, age groups and pathogens.

**Introduction**

Acute respiratory infections (ARI), namely bronchiolitis and pneumonia, are the leading causes of hospital admission and mortality in children <5 years old, worldwide [1–4]. ARI hospitalization rates in young children from circumpolar regions are significantly higher than in temperate areas of the same countries [5–7]. Infants from Inuit Nunangat, the arctic homeland of Inuit in Canada, have some of the highest ever recorded rates of ARI hospitalization, with high proportions requiring intensive care [8–10].

Most communities and villages in Inuit Nunangat are accessible only by air and are served by a local health center or nursing station. As a result, air travel for medical purposes is often inherent in accessing care, representing up to 40% of Nunavut’s healthcare budget, and is a significant contributing factor to per capita spending being more than twice the average for the rest of the country [11–14]. Regional and tertiary pediatric center admissions for ARI are expensive [15], yet cost analyses fail to capture important social and personal costs; families are separated and employment is interrupted for a caregiver to accompany their sick child. Further, it is challenging to navigate cultural and language barriers while accessing care in an unfamiliar healthcare system.

Understanding the epidemiology of ARIs in Northern Canadian populations is important because it can inform priorities for Public Health and the distribution of resources. We sought to describe patient characteristics and microbial etiologies, estimate age-specific tertiary centre admission rates, and explore factors associated with level of care for patients <5 years of age urgently transferred by air for ARI.

**Methods**

**Study design**

This was a multicenter, retrospective cohort study of children <5 years old from Northern Canada transferred by urgent air transport for ARI over a ten-year period (2005–2014) to centers affiliated with the Pediatric Investigators Collaborative Network on Infections in Canada. ARI was defined as an illness of <14 days’ duration with respiratory symptoms suggestive of infection. Based on the typical referral pathways of patients from Northern Canada, admissions to 5 pediatric tertiary care centers were included [16]. The typical referral pathways are from the Yukon to BC Children’s Hospital (BCCH; Vancouver, British Columbia); Kitikmeot region, Western Nunavut and the Northwest Territories to Stollery Children’s Hospital (SCH; Edmonton, Alberta); Kivalliq region, Central Nunavut to Winnipeg Children’s Hospital (WCH; Winnipeg, Manitoba); Qikiqtani region, Eastern Nunavut to Children’s Hospital of Eastern Ontario (CHEO; Ottawa, Ontario) and the three health services regions of Northern Quebec (Nunavik; Terres-Cries-de-la-Baie-James; and Nord-du-Quebec) to Montreal Children’s Hospital (MCH; Montreal, Quebec) [9].

following competing interests: JP has received consulting/honoraria fees from AbbVie and Seegene, and research grant funding outside of the current work from AbbVie, Sanofi Pasteur and MedImmune. DMG has received research grant funding from BioMerieux. The remaining authors declare no conflicts of interest.
Ethics approval was obtained from the following ethics review boards: Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre; Children’s Hospital of Eastern Ontario Research Ethics Board; University of British Columbia Children’s and Women’s Research Ethics Board; Health Research Ethics Board, University of Manitoba; and Health Research Ethics Board, University of Alberta. The requirement of informed consent was waived by all ethics review boards. Only data relevant to this study were collected by the research teams. Data were collected, deidentified and managed using secure REDCap® electronic data capture tools hosted at McGill University Health Centre—Research Institute [17, 18]. The manuscript was reviewed by Nunavut and Nunavik community representatives who provided feedback on result interpretation and presentation.

Case identification

Hospitalizations were identified by querying hospital discharge abstract databases using ARI-specific International Classification of Diseases -9 &10 codes [S1 Data] for patients admitted 2005 through 2014 (at WCH, only data from 2009–2014 were collected due to the large number of cases). Search results were narrowed by patient date of birth in relation to age at time of admission. Search results were narrowed by resident forward sortation areas (geographical unit based on the first three characters of a postal code), as related to each site’s remote Northern catchment areas. This was defined by each study site as follows: children flown in by jet from the Yukon for BCCH, the Northwest Territories or Nunavut for SCH, Nunavut for WCH, Nunavut for CHEO, and Nunavik, Terres-Cries-de-la-Baie-James and Nord-du-Quebec for MCH. Patients electively transferred, such as by scheduled flight instead of air ambulance with advanced care paramedics, or transferred for a reason other than ARI were excluded.

Data collection

Patient paper charts were reviewed by medical students, residents, practicing physicians and research assistants. Data gathering was supervised by each site lead and included informational sessions, training, and the duplication and verification of the first 10 charts performed. Ambiguities and questions were fielded by each study site lead as they arose. In the case of indecipherable handwriting, alternate sources to corroborate data, such as referring center documentation or nursing notes were consulted. Demographics, environmental exposures, clinical history, underlying chronic comorbidities, vaccination history, microbiology of the presenting ARI, hospital course, and outcomes at discharge were collected on standardized case report forms. When more than one pathogen was identified, the site investigator adjudicated which was the likely primary pathogen based on timing, site of detection and the clinical picture. Data were de-identified, coded and entered into REDCap® by a research assistant and/or site investigator, trained by a data entry guide.

Statistical analysis

Descriptive statistics were performed and associations between variables assessed using Chi-square test, Kruskal-Wallis test and relative risks (RR) with associated 95% confidence intervals (CI). Statistical significance was assessed using 2-tailed tests, with an α of 0.05. Annual ARI evacuation incidence rates were calculated using Statistics Canada regional population data over the years of the study for which all 5 centers provided data (2009–2014) [19–21]. Statistical analyses were performed using R version 3.5.2 (R Core Team, Vienna, Austria).
Results

There were 650 eligible admissions to BCCH (n = 8), SCH (n = 89), WCH (n = 194 [from 2009–2014]), CHEO (n = 93) and MCH (n = 266) [Table 1; Fig 1]. Overall, most patients were from Nunavut (n = 349, 53.7%) or Nunavik (n = 166, 25.5%), with the remainder from Terres-Cries-de-la-Baie-James (n = 90, 13.8%), Northwest Territories (n = 28, 4.3%) and Yukon (n = 12, 1.8%). Over half of cases (n = 372; 57.2%) were less than 6 months old, and the majority (n = 458, 70.5%) had no chronic comorbidities. Pre-existing

Table 1. Demographic characteristics of 650 children transported urgently by air from northern Canada to five tertiary care centers (n, %).

| Characteristic | BCCH (N = 8) | SCH (N = 89) | WCH (N = 194) | CHEO (N = 93) | MCH (N = 266) | Total (N = 650) |
|---------------|--------------|--------------|--------------|--------------|--------------|----------------|
| Age in months |
| 0–5 months   | 6 (75.0)     | 43 (48.3)    | 104 (53.6)   | 57 (61.3)    | 162 (60.9)   | 372 (57.2)     |
| 6–11 months  | 1 (12.5)     | 15 (16.8)    | 37 (19.1)    | 15 (16.1)    | 38 (14.3)    | 106 (16.3)     |
| 12–23 months | 1 (12.5)     | 21 (23.6)    | 39 (20.1)    | 14 (15.1)    | 48 (18.0)    | 123 (18.9)     |
| 24–35 months | 0            | 1 (1.1)      | 6 (3.1)      | 4 (4.3)      | 7 (2.6)      | 18 (2.8)       |
| 36–47 months | 0            | 5 (5.6)      | 5 (2.6)      | 3 (3.2)      | 10 (3.8)     | 23 (3.5)       |
| 48–59 months | 0            | 4 (4.5)      | 1 (1.5)      | 0            | 1 (0.4)      | 8 (1.2)        |
| mean (SD)    | 5.2 (7.0)    | 11.8 (14.4)  | 9.4 (10.6)   | 7.9 (9.6)    | 8.2 (10.2)   | 9.0 (10.9)     |
| median (IQR) | 2.1 (1.3–4.9)| 6.4 (2.5–14.4)| 5.4 (2.2–12.4)| 2.7 (1.8–11.3)| 3.4 (1.7–11.9)| 4.2 (1.9–12.3)|
| Sex          | Male         | 4 (50.0)     | 45 (50.6)    | 109 (56.2)   | 59 (63.4)    | 163 (61.3)     | 380 (58.5)     |
| Underlying comorbidity¹ |
| None         | 4 (50.0)     | 82 (92.1)    | 126 (64.9)   | 78 (83.8)    | 168 (63.2)   | 458 (70.5)     |
| Prematurity ≤ 36 weeks gestation | 3 (37.5) | 14 (15.7) | 52 (26.8) | 35 (37.6) | 60 (22.6) | 164 (25.2) |
| Significant cardiac or respiratory condition² | 3 (37.5) | 3 (3.4) | 13 (6.7) | 4 (4.3) | 16 (6.0) | 39 (6.0) |
| Vaccinations up to date for age |
| Yes          | 2 (25.0)     | 55 (61.8)    | 38 (19.6)    | 67 (72.0)    | 78 (29.3)    | 240 (36.9)     |
| No           | 2 (25.0)     | 34 (38.2)    | 156 (80.4)   | 26 (28.0)    | 188 (70.7)   | 406 (62.5)     |
| Unknown      | 4 (50.0)     | 0            | 0            | 0            | 0            | 4 (0.6)        |
| Smokers in the household |
| Yes          | 0            | 15 (16.8)    | 112 (57.7)   | 67 (72.0)    | 78 (29.3)    | 272 (41.8)     |
| No           | 4 (50.0)     | 5 (5.6)      | 32 (16.5)    | 2 (2.1)      | 5 (1.9)      | 48 (7.4)       |
| Not recorded | 4 (50.0)     | 69 (77.5)    | 50 (25.8)    | 24 (25.8)    | 183 (68.8)   | 330 (50.8)     |
| Forward Sortation Area |
| Nunavut (X0A, X0B, X0C) | 0 | 54 (60.7) | 194 (100) | 93 (100) | 8 (3.0) | 349 (53.7) |
| RSS Nunavik (J0M)³ | 0 | 0 | 0 | 0 | 166 (62.4) | 166 (25.5) |
| RSS Terres-Cries-de-la-Baie-James (G0W, J0Y, J0M)⁴ | 0 | 0 | 0 | 0 | 90 (33.8) | 90 (13.8) |
| Northwest Territories (X0E, X0G and X1A) | 0 | 28 (31.5) | 0 | 0 | 0 | 28 (4.3) |
| Yukon (Y—) | 8 (100)      | 4 (4.5)      | 0            | 0            | 0            | 12 (1.8)       |
| RSS Nord du Quebec (G8P) | 0 | 0 | 0 | 0 | 2 (0.8) | 2 (0.3) |

BCCH BC Children’s Hospital; CHEO Children’s Hospital of Eastern Ontario; IQR Interquartile range; MCH Montreal Children’s hospital; RSS Région sociosanitaires; SCH Stollery Children’s Hospital; SD Standard Deviation; WCH Winnipeg Children’s Hospital

¹ Additional details on individual underlying comorbidities are presented in S1 Table of the Supplementary Information.

² Defined as hemodynamically significant heart disease and/or chronic lung disease of prematurity.

³ Defined as any of the 14 communities considered as part of Nunavik (RSS17) with FSA of J0M: Akulivik, Aupaluk, Inukjuak, Ivujivik, Kangiqsualujjuaq, Kangiqsualujjuaq, Kangirsuk, Kuujjuaraapik, Puvirnituq, Quaqtaq, Salluit, Tasiujaq, Umiujaq.

⁴ Includes the following communities with FSAs of G0W, J0Y or J0M: Chisasibi, Eastmain, Mistissini, Nemaska, Ouje-bougoumou, Waswanipi, Whapmagoostui, Wemindji that are part of the RSS 18 (Terres-Cries-de-la-Baie-James).

https://doi.org/10.1371/journal.pone.0272154.t001

PLOS ONE | https://doi.org/10.1371/journal.pone.0272154 July 28, 2022 4 / 15
chronic medical conditions are presented in S1 Table. There was insufficient information from chart review to reliably report household overcrowding (missingness, n = 225 [34.6%]), presence of household smokers (missingness, n = 330 [50.8%]), and family history of atopy or asthma (missingness, n = 547 [84.1%]).

Estimated annual tertiary care ARI admission rates in children <1 year old during 2009 to 2014 ranged from 2.0/1000 infants in the Northwest Territories to 44.5/1000 infants in Nunavik [Table 2]. Among patients 1–4 years old, yearly admission rates ranged from 0.1/1000 children in the Yukon to 3.9/1000 children in Nunavut. Incidence rates were not estimated for the Nord-du-Quebec region, as only 1 admission was observed during that time period.

Admitting diagnoses and clinical manifestations are presented in S2 Table. Bronchiolitis (51.2%) and pneumonia (32.0%) were the most common primary discharge diagnoses [Table 3]. Regional Northern hospitalization, prior to transfer, varied greatly: the majority of WCH patients arrived directly from nursing stations (n = 179, 92.3%), whereas regional hospitals admitted most patients prior to transfer to SCH (n = 81, 91.0%), CHEO (n = 85, 91.4%)

Table 2. Annual tertiary care acute respiratory infection related admission rates (per 1,000 population) of children transported urgently by air from five northern Canada regions between 2009 to 2014.

| Region                        | <1 year (95% CI) | 1–4 years (95% CI) |
|-------------------------------|------------------|-------------------|
| Yukon (N = 9)                 | 3.3 (0.7–15.0)   | 0.1 (0.004–2.6)   |
| Northwest Territories (N = 16)| 2.0 (0.4–9.1)   | 0.5 (0.1–2.4)     |
| Nunavut (N = 280)             | 40.7 (29.3–56.4) | 3.9 (2.3–6.7)     |
| Nunavik (N = 104)             | 44.5 (26.8–72.9) | 2.5 (0.8–7.3)     |
| Terres-Cries-de-la-Baie-James (N = 48)| 13.5 (5.8–31.3)| 1.9 (0.7–5.7) |

CI Confidence interval

1 Incidence rates were not estimated for the Nord-du-Quebec region, as only 1 admission was observed during that time period.

https://doi.org/10.1371/journal.pone.0272154.t002
Table 3. Clinical characteristics of 650 children transported urgently by air from northern Canada to five tertiary care centers (n, %).

| | BCCH (N = 8) | SCH (N = 89) | WCH (N = 194) | CHEO (N = 93) | MCH (N = 266) | Total (N = 650) |
|---|---|---|---|---|---|---|
| Regional hospitalization prior to transfer | 1 (12.5) | 81 (91.0) | 15 (7.7) | 85 (91.4) | 231 (86.8) | 420 (64.6) |
| Duration of symptoms prior to admission to study center (median days, IQR) | 3.0 (3.0–5.5) | 5.0 (2.5–11.0) | 4.0 (2.0–6.0) | 4.0 (3.0–6.0) | 4.0 (3.0–6.0) | 4.0 (3.0–6.0) |
| Received care in ICU | 3 (37.5) | 58 (65.2) | 38 (19.6) | 71 (76.3) | 146 (54.9) | 316 (48.6) |
| Highest respiratory support | | | | | | |
| No respiratory support | 4 (50.0) | 19 (21.3) | 56 (28.9) | 8 (8.6) | 53 (19.9) | 140 (21.5) |
| Oxygen only | 2 (25.0) | 31 (34.8) | 108 (55.7) | 27 (29.0) | 85 (31.9) | 253 (38.9) |
| Any CPAP/BiPAP | 0 | 0 | 16 (8.2) | 6 (6.4) | 30 (11.3) | 52 (8.0) |
| Any mechanical ventilation or HFOV | 2 (25.0) | 39 (43.8) | 14 (7.2) | 52 (55.9) | 98 (36.8) | 205 (31.5) |
| Antimicrobial therapy | NA1 | 80 (89.9) | 142 (73.2) | 86 (92.5) | 218 (82.0) | 526 (80.9) |
| Procedures done at study site | | | | | | |
| Lumbar puncture | 0 | 9 (10.1) | 24 (12.4) | 32 (34.4) | 37 (13.9) | 102 (15.7) |
| Procedure requiring general anesthesia | 0 | 5 (5.6) | 0 | 10 (10.8) | 40 (15.0) | 55 (8.5) |
| Tube thoracostomy | 0 | 8 (9.0) | 0 | 5 (5.4) | 14 (5.3) | 27 (4.1) |
| Thoracentesis | 0 | 1 (1.1) | 0 | 1 (1.1) | 9 (3.4) | 11 (1.7) |
| Length of stay at tertiary care center (days) | | | | | | |
| Mean (SD) | 7.9 (7.4) | 13.4 (13.9) | 5.4 (6.2) | 18.4 (18.5) | 14.2 (19) | 12.0 (16.0) |
| Median (IQR) | 5.0 (2.0–12.0) | 10.0 (5.0–15.0) | 4.0 (2.0–7.0) | 13.0 (9.0–22.0) | 9.0 (5.0–18.0) | 7.0 (4.0–14.0) |
| Primary discharge diagnosis | | | | | | |
| Bronchiolitis | 6 (75.0) | 41 (46.1) | 102 (52.6) | 56 (60.2) | 128 (48.1) | 333 (51.2) |
| Pneumonia | 0 | 24 (27.0) | 88 (45.4) | 19 (20.4) | 77 (28.9) | 208 (32.0) |
| Other | 2 (25.0) | 19 (21.3) | 2 (1.0) | 10 (10.7) | 52 (19.5) | 85 (13.1) |
| Apnea | 0 | 2 (2.2) | 0 | 5 (5.4) | 5 (1.9) | 12 (1.8) |
| Asthma/reactive airway disease | 0 | 1 (1.1) | 1 (0.5) | 2 (2.2) | 3 (1.1) | 7 (1.1) |
| Empyema | 0 | 1 (1.1) | 0 | 1 (1.1) | 0 | 2 (0.3) |
| Sepsis/shock | 0 | 0 | 1 (0.5) | 0 | 1 (0.4) | 2 (0.3) |
| Pleural effusion | 0 | 1 (1.1) | 0 | 0 | 0 | 1 (0.1) |
| Previous admissions to study centre | | | | | | |
| Yes | 3 (37.5) | 14 (15.7) | 49 (25.3) | 10 (10.8) | 53 (19.9) | 129 (19.8) |
| Not recorded | 0 | 29 (32.6) | 2 (1.0) | 0 | 2 (0.8) | 33 (5.1) |
| Final disposition | | | | | | |
| Discharged home | 6 (75.0) | 61 (68.5) | 194 (100.0) | 93 (100.0) | 262 (98.5) | 616 (94.8) |
| Transfer to other hospital | 2 (25.0) | 19 (21.3) | 0 | 0 | 1 (0.4) | 22 (3.4) |
| Transfer to long-term care facility/rehab | 0 | 7 (7.9) | 0 | 0 | 0 | 7 (1.1) |
| Death in hospital | 0 | 1 (1.1) | 0 | 0 | 2 (0.8) | 3 (0.5) |
| Unknown | 0 | 1 (1.1) | 0 | 0 | 0 | 1 (0.1) |

BCCH BC Children’s Hospital; BiPAP Bilevel Positive Airway Pressure; CHEO Children’s Hospital of Eastern Ontario; CPAP Continuous Positive Airway Pressure; CPR Cardiopulmonary resuscitation; ECMO Extracorporeal membrane oxygenation; HFOV High Frequency Oscillatory Ventilation; ICU Intensive care unit; IQR Interquartile range; MCH Montreal Children’s hospital; NA Not available; SCH Stollery Children’s Hospital; SD Standard Deviation; WCH Winnipeg Children’s Hospital

1 Data on antimicrobial use was not collected at BCCH.

https://doi.org/10.1371/journal.pone.0272154.1003

and MCH (n = 231, 86.8%). WCH had the lowest hospital median length of stay (4 days) and lowest proportion requiring ICU care (n = 38, 19.6%) while CHEO had the highest length of stay (13 days, p<0.001) and proportion requiring ICU care (n = 71, 76.3%, p<0.001). Overall,
48.6% of children were admitted to ICU; 31.5% received mechanical ventilation. Age <6 months (RR 1.51, 95%CI 1.04–2.21), and history of prematurity (1.25, 95%CI 1.06–1.48) were associated with ICU admission [S3 Table]. Compared with admissions with no pathogen identified, the risk of ICU admission was higher if RSV, other non-influenza respiratory viruses, B. pertussis or H. influenzae were the primary pathogen. The highest level of respiratory support varied significantly across age groups, primary pathogen identified and history of prematurity or any chronic comorbidity [S4 Table].

At least one potential etiologic agent was detected in 430 cases (66.1%) [Table 4]. Fig 2 presents the distribution of identified primary and secondary pathogens across age groups. Overall,

Table 4. Microbiology results of 650 children transported urgently by air from northern Canada to five tertiary care centers (n, %).

| Lab confirmation of etiologic agent | BCCH (N = 8) | SCH (N = 89) | WCH (N = 194) | CHEO (N = 93) | MCH (N = 266) | Total (N = 650) |
|------------------------------------|-------------|-------------|---------------|---------------|---------------|----------------|
| Primary pathogen identified         |             |             |               |               |               |                |
| RSV                                | 6 (75.0)    | 28 (31.4)   | 50 (25.8)     | 28 (30.1)     | 87 (32.7)     | 196 (30.1)     |
| Adenovirus                         | 3 (37.5)    | 7 (7.9)     | 13 (6.7)      | 2 (2.2)       | 15 (5.6)      | 37 (5.7)       |
| Rhinovirus                         | 0           | 0           | 8 (4.1)       | 0             | 26 (9.8)      | 34 (5.2)       |
| Parainfluenza virus                | 0           | 6 (6.7)     | 8 (4.1)       | 2 (2.2)       | 16 (6.0)      | 32 (4.9)       |
| Type 1                             | 0           | 0           | 2 (1.0)       | 0             | 4 (1.5)       | 6 (0.9)        |
| Type 2                             | 0           | 0           | 0             | 0             | 0             | 0              |
| Type 3                             | 0           | 1 (1.1)     | 5 (2.6)       | 2 (2.2)       | 11 (4.1)      | 19 (2.9)       |
| Type 4                             | 0           | 0           | 0             | 0             | 0             | 0              |
| Influenza A                        | 0           | 6 (6.7)     | 6 (3.1)       | 4 (4.3)       | 3 (3.4)       | 25 (3.8)       |
| H1N1 subtype                       | 0           | 5 (5.6)     | 4 (2.1)       | 1 (1.1)       | 4 (1.5)       | 14 (2.1)       |
| H3N2 subtype                       | 0           | 0           | 0             | 2 (0.8)       | 2 (0.3)       |                |
| hMPV                               | 1 (12.5)    | 2 (2.2)     | 5 (2.6)       | 5 (5.4)       | 11 (4.1)      | 24 (3.7)       |
| H. influenzae                      | 1 (12.5)    | 3 (3.4)     | 1 (0.5)       | 3 (3.2)       | 6 (2.2)       | 14 (2.1)       |
| Rhinovirus/Enterovirus             | 0           | 11 (12.4)   | 1 (0.5)       | 1 (1.1)       | 0             | 13 (2.0)       |
| Influenza B                        | 0           | 0           | 4 (2.1)       | 0             | 6 (2.3)       | 10 (1.5)       |
| Enterovirus                        | 0           | 0           | 1 (0.5)       | 2 (2.2)       | 5 (1.9)       | 8 (1.2)        |
| B. pertussis                       | 0           | 1 (1.1)     | 1 (0.5)       | 2 (2.2)       | 4 (1.5)       | 8 (1.2)        |
| Other bacteria                     | 1 (12.5)    | 2 (2.2)     | 1 (0.5)       | 0             | 3 (1.1)       | 7 (1.1)        |
| Group A strep                      | 0           | 2 (2.2)     | 0             | 1 (1.1)       | 3 (1.1)       | 6 (0.9)        |
| S. pneumoniae                     | 0           | 0           | 2 (1.0)       | 0             | 3 (1.1)       | 5 (0.8)        |
| Coronavirus                        | 0           | 1 (1.1)     | 2 (1.0)       | 0             | 1 (0.4)       | 4 (0.6)        |
| MRSA                               | 0           | 1 (1.1)     | 1 (0.5)       | 0             | 1 (0.4)       | 3 (0.5)        |
| Group B strep                      | 0           | 0           | 0             | 0             | 2 (0.8)       | 2 (0.3)        |
| MSSA                               | 0           | 1 (1.1)     | 0             | 0             | 0             | 1 (0.1)        |
| Other organism                     | 0           | 0           | 0             | 1 (0.4)       | 1 (0.4)       | 1 (0.1)        |
| TB                                 | 0           | 0           | 0             | 0             | 0             | 0              |
| Laboratory confirmed concurrent infection | 0 | 17 (19.1) | 23 (11.8) | 8 (8.6) | 37 (13.9) | 85 (13.1) |

B Bordetella; BCCH BC Children’s Hospital; CHEO Children’s Hospital of Eastern Ontario; H Haemophilus; hMPV human metapneumovirus; IQR Interquartile range; MCH Montreal Children’s hospital; MSSA meticillin-sensitive staphylococcus aureus; MRSA meticillin-resistant Staphylococcus aureus; RSV Respiratory Syncytial Virus; S Streptococcus; SCH Stollery Children’s Hospital; SD Standard Deviation; strep streptococcus; TB tuberculosis; WCH Winnipeg Children’s Hospital

1 Acinetobacter spp (n = 1)
2 M. catarrhalis (n = 2)
3 Acinetobacter spp (n = 1)
4 S. viridans (n = 2), C. trachomatis (n = 1)
5 Cytomegalovirus (n = 1)

https://doi.org/10.1371/journal.pone.0272154.t004
RSV was the most common primary pathogen (n = 196, 30.1%) and was detected approximately three times more frequently in children < 6 months of age (n = 126, 33.9%) than in those 2–4 years old (n = 6, 12.2%). Influenza A or B were detected in 5.4% (n = 35) of cases. Other non-influenza respiratory viruses were the primary pathogen in 23.5% (n = 153). Potentially vaccine-preventable bacteria (S. pneumoniae, H. influenzae and B. pertussis) were the primary pathogens in 27 cases (4.1%). Overall, there was more than one laboratory confirmed infection identified in 13.1% (n = 85) of admissions. Although laboratory-confirmed bacterial infection was uncommon (46 primary infections [7.1%]; 29 secondary infections [4.5%]), 8 out of every 10 cases were treated with antibiotics.

**Discussion**

This is the first Canada-wide collaborative epidemiologic study of pediatric tertiary care center ARI admissions from Northern Canada. We found very high yearly admission rates in both Nunavut (40.7 per 1000 infants) and Nunavik (44.5 per 1000 infants) among children less than one year of age, which were tenfold higher than for children 2–4 years old. Tertiary care admission rates from the Yukon and Northwest Territories were comparatively much lower, at 3.3 per 1000 infants and 2.0 per 1000 infants yearly, respectively [22]. Our estimated hospitalization rates represent the subset of patients with the highest ARI severity that require urgent air transfer to a pediatric tertiary care center; as such, they are predictably smaller than previously reported staggeringly high regional ARI admission rates in Nunavut of 306 to 590 per 1000 infants less than one year of age [5, 8, 9, 23]. In comparison, North American bronchiolitis
admission rates overall have trended down to 11.8–13.5 per 1000 infants less than one year of age [24, 25]. Similarly, Australian aboriginal children and Alaska Native infants also experience a several factor-fold higher rate of admission for ARIs compared to national rates for the same age groups [7, 26].

Admission rates in this study reflect a spectrum of disease severity and merit descriptive nuance. First, we observed significantly different admission profiles between the five tertiary care centers involved in our study. Whereas the vast majority of WCH admissions were transferred directly from nursing stations to WCH without intermediate regional hospitalization, the MCH receives transfers from regional hospitals staffed mainly by primary care providers with consulting paediatricians. The significantly higher number of admissions to WCH and less severe case-mix are likely a reflection of infrequent regional hospitalization prior to transfer. The lack of regional care is an increasing trend in North America and leads to transfer as a rule, with loss of regional pediatric capacity and little room to surge [27]. SCH and CHEO’s transfers generally hail from larger centers, Stanton Territorial Hospital (STH) in Yellowknife and Qikiqtani General Hospital (QGH) in Iqaluit, that have benefitted from improved access to on-site care from full-time pediatricians. This specialized care in a general hospital likely decreases the overall number of transfers, but results in an increased proportion of transfers that require PICU admission and invasive mechanical ventilation. A qualitative study in Nunavut has suggested that transfers reflect both the referring and receiving providers’ experience and the staffing in health centres, with there being challenges related to recruitment and retention of staff [28]. The availability of specialized care, including diagnostic tests and treatments such as early provision of non-invasive respiratory support, could reduce the need for transfer to a Southern referral center [29]. With the expanding role of telemedicine, which has benefitted from much greater uptake and technological developments since the start of the COVID-19 pandemic, this could alleviate some stress on staffing issues. On the other hand, the very few admissions from the Yukon may reflect intermediate hospitalization at Whitehorse General Hospital, which has paediatrician coverage, as well as a more urban and lower risk population. Nevertheless, when taken as a whole, these transfers from Northern Canada represent severe cases of ARI, with nearly half (48.6%) of the children in the cohort requiring admission to ICU and very high rates of invasive mechanical ventilation (31.5%). In other parts of North America, Europe and Australia, rates of intubation and mechanical ventilation for young children admitted with bronchiolitis or pneumonia are consistently far lower at 1.6%-7% [3, 25, 30–33].

The reason for the exceptional ARI burden in this population is likely multifactorial. There are demonstrated relationships between LRTIs and social determinants of health, including high rates of overcrowding in homes, poor indoor air quality, remote residence, and smoking during pregnancy [6, 10, 34–37]. Due to the retrospective nature of this study, it was not possible to collect accurate data on ethnicity and on social and environmental risk factors. Additionally, many children arrived at tertiary care centers unaccompanied by parents due to historical policies that prevented parents from boarding medical evacuation flights [38] which further impaired collection of such information. Data available through the 2018 Inuit Statistical profile indicates that 52% of Inuit homes are overcrowded, 70% households are food insecure and 63% of residents 12 years of age and older report daily cigarette smoking [39]. Given the enormous impact of the social determinants of health, this is an aspect of medical history taking and care that requires emphasis.

A primary pathogen was microbiologically identified in approximately two-thirds of patients with about one-third having RSV. Among infants less than 6 months of age, 33.9% (n = 126) had RSV, as did 31.1% (n = 33) of those between 6 and 11 months. This proportion is comparable to published data from infants admitted for bronchiolitis in Northern Canada.
or for community-acquired pneumonia in the United States [3] and in low-middle income countries [2]. Although there is no licensed vaccine for RSV, passive immunoprophylaxis with palivizumab has been shown to be safe and effective at preventing RSV-associated hospitalization in specific high-risk infant groups [41, 42]. Drawbacks of an immunoprophylaxis strategy include the high cost ($5,000-$9,000 per infant per year), monthly injections during RSV season [43], in addition to the administrative challenge of identifying and tracking eligible patients [44]. However, it has been estimated that direct costs of admission to Qikiqtani General Hospital in Nunavut averaged $14,273 CAD in 2005, and a transfer to CHEO in Ottawa costs upwards of $45,000 CAD [45–47]. Two Canadian cost-effectiveness analyses have suggested that universal palivizumab prophylaxis for infants <6 months of age would be cost-saving in some, but not all, rural Arctic communities [44] and the Canadian Pediatric Society stated that palivizumab immunoprophylaxis may be considered in term Inuit infants <6 months of age during RSV season if they live in communities with documented persistent high rates of RSV hospitalization. Unfortunately, theory has not translated well to practice: in Quebec, from 2016–2017 through to 2019–2020, the provincial program was expanded to include healthy term Nunavik infants <3 months old and in the three seasons studied, there was no evidence that palivizumab reduced RSV hospitalizations in that population [48]. Preventing RSV infection in young children living in remote settings has been identified as a public health priority by the Public Health Agency of Canada [49]. As roughly two-thirds of urgent air transfers for ARI in this population appear to be due to pathogens other than RSV, strategies to address ARI prevention more broadly are sorely needed, such as optimizing routine vaccination coverage, smoking cessation, reducing household crowding, improving food security and timely access to appropriate diagnosis and management. Indeed, the COVID-19 pandemic has demonstrated that non-pharmacological interventions to slow SARS-COV-2 transmission also significantly reduced the overall rates of emergency department visits and hospitalizations for pediatric infectious illnesses [50–53].

Regarding other potentially vaccine-preventable illnesses, pertussis was uncommon (8 cases identified) but associated with need for ICU admission (100%) and mechanical ventilation (50%). Influenza was infrequently detected in infants (<5%), but was associated with 13.8% (n = 17) and 12.2% (n = 6) of admissions in the 12–23 month-old and 24–59 month-old age brackets, respectively. The report of an up-to-date vaccination schedule varied widely in subjects from different study sites (19.6% to 72.0%). This highlights an area of inexpensive, preventable illness that can get lost with barriers to care, such as a pandemic, geographical or weather-induced isolation and the need for research into optimizing vaccination scheduling and adherence in this vulnerable population [54, 55].

This study has several limitations. Patients deceased prior to transfer would have been missed, as would patients that deviated from habitual transfer routes due to weather or bed-space limitations. Further, the retrospective nature of the data collection makes gathering information about the social history difficult. Previous palivizumab receipt may not have been recorded in hospital charts, especially for infants in a non-traditional high risk group. Microbiologic testing was not uniformly performed; in particular, the availability of highly-multiplexed PCR panels, the gold standard for respiratory virus diagnostics [56, 57], varied over time and by site.

In conclusion, urgent air transfers for severe ARI in infants from Northern Canada are common and are associated with a high level of acuity, including need for critical care and mechanical ventilation, especially in children <1 year-old. This disease burden is likely a reflection of access to local care and resources, but also of social inequity and socio-economic status. Urgent attention to this topic is warranted and there is a pressing need for public health
strategies and interventions to decrease the risk of severe ARI and improve the health of young children in remote settings.

**Supporting information**

S1 Table. Underlying chronic medical conditions (n, %).
(DOCX)

S2 Table. Admitting diagnoses and presenting manifestations (n, %).
(DOCX)

S3 Table. Intensive care unit requirements by age group, primary pathogen, and comorbidity.
(DOCX)

S4 Table. Highest respiratory support received by age group, primary pathogen, and comorbidity.
(DOCX)

S5 Table. Urgent air transfers to four tertiary care centers by region in Nunavut (n, %).
(DOCX)

S1 Data. ICD-10 Diagnostic codes related to ARI.
(DOCX)

**Acknowledgments**

We thank community representatives from Nunavut and Nunavik and for providing feedback to improve the manuscript.

**Author Contributions**

**Conceptualization:** Caitlin Prendergast, Joan Robinson, David M. Goldfarb, Radha Jetty, Joanne Embree, Jesse Papenburg.

**Data curation:** Jesse Papenburg.

**Formal analysis:** Chelsea Caya, Maria E. Perez Trejo, Nick Barrowman.

**Investigation:** Caitlin Prendergast, Joan Robinson, Iline Guan, Veronica Hébert-Murakami, Justina Marianayagam, Zing-Wae Wong, Celia Walker, David M. Goldfarb, Radha Jetty, Joanne Embree.

**Supervision:** Jesse Papenburg.

**Visualization:** Caitlin Prendergast, Chelsea Caya.

**Writing – original draft:** Caitlin Prendergast.

**Writing – review & editing:** Caitlin Prendergast, Joan Robinson, Chelsea Caya, Maria E. Perez Trejo, Iline Guan, Veronica Hébert-Murakami, Justina Marianayagam, Zing-Wae Wong, Celia Walker, David M. Goldfarb, Nick Barrowman, Radha Jetty, Joanne Embree, Jesse Papenburg.

**References**

1. Wang H, Naghavi M, Allen C, Barber RM, Carter A, Casey DC, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a
systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1459–544. https://doi.org/10.1016/S0140-6736(16)31012-1 PMID: 27733281

2. O’Brien KL, Baggett HC, Brooks WA, Feikin DR, Hammit LL, Higdon MM, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019; 394(10200):757–79. https://doi.org/10.1016/S0140-6736(19)30721-4 PMID: 31257127

3. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372(9):835–45. https://doi.org/10.1056/NEJMoa1405870 PMID: 25714161

4. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390(10098):946–58. https://doi.org/10.1016/S0140-6736(17)30938-8 PMID: 28689664

5. Banerji A, Bell A, Mills EL, McDonald J, Subbarao K, Stark G, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ. 2001; 164(13):1847–50. PMID: 11450280

6. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012; 17(7):376–80. PMID: 23904781

7. Bruden DJ, Singleton R, Hawk CS, Bulkow LR, Bentley S, Anderson LJ, et al. Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children. Pediatr Infect Dis J. 2015; 34(9):945–50. https://doi.org/10.1097/INF.0000000000000772 PMID: 26565863

8. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health. 2007; 12(7):563–6. PMID: 19004026

9. Banerji A, Panzov V, Young M, Robinson J, Lee B, Moraes T, et al. Hospital admissions for lower respiratory tract infections among infants in the Canadian Arctic: a cohort study. CMAJ Open. 2016; 4(4):E615–E622. https://doi.org/10.9778/cmajo.20150051 PMID: 28018874

10. He H, Xiao L, Torrie JE, Auger N, McHugh NG, Zougrana H, et al. Disparities in infant hospitalizations in Indigenous and non-Indigenous populations in Quebec, Canada. CMAJ. 2017; 189(21):E739–E746. https://doi.org/10.1503/cmaj.160990 PMID: 28554947

11. Young TK, Tabish T, Young SK, Healey G. Patient transportation in Canada’s northern territories: patterns, costs and providers’ perspectives. Rural Remote Health. 2019; 19(2):5113. https://doi.org/10.22605/RRH5113 PMID: 31128577

12. McKenzie C. Medevac and Beyond: The Impact of Medical Travel on Nunavut Residents / ᑲᓇᑕᒥ ᒪᓐᓛᕐᓂᖅ ᐊᒻᒪᓗ ᓐᓂᐊᕕᓕᐊᖅᐸᑦᑐᑦ ᐊᑦᑐᖅᑕᐅᓂᕆᕙᑦᑕᖏᑦ. Int J Indig Health. 2015; 9(2):80–8. https://doi.org/10.18357/ijih92201214365

13. Canadian Institute for Health Information. How does Canada’s health spending compare? [Internet]. Canadian Institute for Health Information [cited 2022 Feb 8]. Available from: https://www.cihi.ca/en/how-does-canadas-health-spending-compare.

14. Statista. Provincial/territorial government sector health expenditure per capita in Canada in 2021, by province. [Internet]. Statista [cited 2022 Feb 6]. Available from: https://www.statista.com/statistics/436343/governmental-health-expenditure-per-capita-canada-by-province/#:~:text=Text%20was%20forecasted%20that%20in,20health%20care%20per%20capita.

15. Creery D, Lyer P, Samson L, Coyle D, Osborne G, MacDonald A. Costs associated with infant bronchiolitis in the Baffin region of Nunavut. Int J Circumpolar Health. 2005; 64(1):38–45. https://doi.org/10.3402/ijch.v64i1.17952 PMID: 15776991

16. Banerji A, Panzov V, Young M, Lee BE, Mamdani M, Giles BL, et al. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut. Can Respir J. 2014; 21(3):185–9. https://doi.org/10.1155/2014/941367 PMID: 24367792

17. Harris PA, Taylor R, Thielle R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010 PMID: 18929666

18. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. https://doi.org/10.1016/j.jbi.2019.103208 PMID: 31078660

19. Government of Nunavut. Population Data: Nunavut Population Estimates by Sex and Single Years of Age, 1998 to 2021, as of July 1. [Internet]. Government of Nunavut [cited 2022 Feb 14 21]. Available from: https://www.gov.nu.ca/executive-and-intergovernmental-affairs/information/population-data.
20. Institut de la statistique du Québec. Estimations de la population des MRC selon l’âge et le sexe, âge médian et âge moyen, Québec, 1er juillet 1996 à 2020. [Internet]. Institut de la statistique du Québec [cited 2021 Feb 18]. Available from: https://statistique.quebec.ca/fr/document/population-et-structure-par-age-et sexe-municipalites-regionales-de-cont-me-mrc.

21. Statistics Canada. Table 17-10-0005-01 Population estimates on July 1st, by age and sex. [Internet]. Statistics Canada [cited 2021 Jan 22]. Available from: https://www15.statcan.gc.ca/n1/fbl/csv/17100005-eng.zip.

22. Statistics Canada. Focus on Geography Series, 2016 Census. [Internet]. Statistics Canada [cited 2021 Jan 11]. Available from: https://www12.statcan.gc.ca/census-recenement/2016/as-sa/fpg-Facts-PR-Eng.cfm?TOPIC=9&LANG=Eng&GC=PR&GC=60.

23. Banerji A. High rates of hospitalisation for bronchiolitis in Inuit children on Baffin Island. Int J Circumpolar Health. 2001; 60(3):375–9. PMID: 11590877

24. Inagaki K, Blackshear C, Burns PA, Hobbs CV. Racial/Ethnic Disparity in the Incidence of Bronchiolitis Requiring Hospitalization. Clin Infect Dis. 2021; 72(4):668–74. https://doi.org/10.1093/cid/ciaa113 PMID: 32020165

25. Fujiogi M, Goto T, Yasunaga H, Fujishiro J, Mansbach JM, Camargo CA Jr., et al. Trends in Bronchiolitis Hospitalizations in the United States: 2000–2016. Pediatrics. 2019; 144(6):E20192614. https://doi.org/10.1542/peds.2019-2614 PMID: 31699829

26. Moore H, Burgner D, Carville K, Jacoby P, Richmond P, Lehmann D. Diverging trends for lower respiratory infections in non-Aboriginal and Aboriginal children. J Paediatr Child Health. 2007; 43(6):451–7. https://doi.org/10.1111/j.1440-1754.2007.01110.x PMID: 17535175

27. Cushing AM, Bucholz EM, Chien AT, Rauch DA, Michelson KA. Availability of Pediatric Inpatient Services in the United States. Pediatrics. 2021; 148(1):E2020041723. https://doi.org/10.1542/peds.2020-041723 PMID: 34127553

28. McDonnell L, Lavoie JG, Healy G, Wong S, Goulet S, Clark W. Non-clinical determinants of Medevacs requiring hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study. Pediatr Infect Dis J. 2021; 10(3):237–44. https://doi.org/10.1093/jpids/piaa046 PMID: 32530035

29. Franklin D, Fraser JF, Schibler A. Respiratory support for infants with bronchiolitis, a narrative review of the literature. Paediatr Respir Rev. 2019; 30:16–24. https://doi.org/10.1016/j.prrv.2018.10.001 PMID: 31076380

30. Suessman A, Gray LL, Cavenaugh S, Camp EA, Shi Y, Meskill SD. Clinical factors associated with intubation in the high flow nasal cannula era. Am J Emerg Med. 2020; 38(12):2500–5. https://doi.org/10.1016/j.ajem.2019.12.017 PMID: 31948785

31. Green CA, Yeates D, Goldacre A, Sande C, Parslow RC, McShane P, et al. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Arch Dis Child. 2016; 101(2):140–6. https://doi.org/10.1136/archdischild-2015-308723 PMID: 26342094

32. Ganu SS, Gautam A, Wilkins B, Egan J. Increase in use of non-invasive ventilation for infants with severe bronchiolitis is associated with decline in intubation rates over a decade. Intensive Care Med. 2012; 38(7):1177–83. https://doi.org/10.1007/s00134-012-2566-4 PMID: 22527081

33. Papenburg J, Defoy I, Massé E, Caouette G, Lebel MH. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study. J Pediatr Infect Dis Soc. 2021; 10(3):237–44. https://doi.org/10.1093/jpids/piaa046 PMID: 32530035

34. Banerji A, Greenberg D, White LF, Macdonald WA, Saxton A, Thomas E, et al. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study. Pediatr Infect Dis J. 2009; 28(8):697–701. https://doi.org/10.1097/INF.0b013e3181f1f89 PMID: 17638953

35. Kovesi T, Gilbert NL, Stocco C, Fuqer D, Dales RE, Guay M, et al. Indoor air quality and the risk of lower respiratory tract infections in young Canadian Inuit children. CMAJ. 2007; 177(2):155–60. https://doi.org/10.1503/cmaj.061574 PMID: 17535175

36. Li JS, Peat JK, Xuan W, Berry G. Meta-analysis on the association between environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory tract infection in early childhood. Pediatr Pulmonol. 1999; 27(1):5–13. https://doi.org/10.1002/sccii.1099990127;1:<5:aid-pulld>3.0.co;2-5 PMID: 10023785

37. Jansson N, Nilsson P, Olsson M. Socioeconomic environmental factors and hospitalization for acute bronchiolitis during infancy. Acta Paediatr. 2002; 91(3):335–8. https://doi.org/10.1080/08035250252834021 PMID: 12022309
38. Shaheen-Hussain S. Decolonizing Health Care: Confronting Medical Colonialism against Indigenous Children. [Internet]. CPS 2020 [cited 2020 Jul 22]. Available from: https://www.cps.ca/en/blog-blogue/ decolonizing-health-care-confronting-medical-colonialism-against-indigenous-children.

39. Inuit Tapiriit Kanatami (ITK). 2008 Inuit Statistical Profile. [Internet]. Inuit Tapiriit Kanatami 2016 [cited 2020 Jul 22]. Available from: https://www.itk.ca/wp-content/uploads/2016/07/InuitStatisticalProfile2008_0.pdf.

40. McCuskee S, Kirlew M, Kelly L, Fewer S, Kovess T. Bronchiolitis and pneumonia requiring hospitalization in young first nations children in Northern Ontario, Canada. Pediatr Infect Dis J. 2014; 33(10):1023–6. https://doi.org/10.1097/INF.0000000000000361 PMID: 24751861

41. The IMpact-RSV Study Group. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization Due to Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998; 102(3):531–7. PMID: 9724660

42. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143(4):532–40. https://doi.org/10.1067/s0022-3476(03)00454-2 PMID: 14571236

43. Government of Nunavut, Department of Health. Nunavut Immunization Manual: 11.0 Specialized and Annual Immunization Protocols. [Internet]. Government of Nunavut 2014 [cited 2021 Jan 11]. Available from: https://www.gov.nu.ca/sites/default/files/synagis_protocol_package_season_2016_01december2015_final.docx.pdf.

44. Lorcy A, Gilca R, Dubé E, Rochette M, De Serres G. Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec. Int J Circumpolar Health. 2020; 79(1):1742564. https://doi.org/10.1080/22423982.2020.1742564 PMID: 32191589

45. Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J. 2009; 29(8):702–6. https://doi.org/10.1097/INF.0b013e31819df78e PMID: 19461555

46. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ. 2009; 12(4):361–70. https://doi.org/10.3111/1369699090412155 PMID: 19000791

47. Robinson JL, Le Saux N. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015; 20(6):321–33. https://doi.org/10.1093/pch/20.6.321 PMID: 26435673

48. Gilca R, Billard MN, Zafack J, Papenburg J, Boucher FD, Charest H, et al. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term infants from the circumpolar region of Nunavik, Quebec, Canada. Prev Med Rep. 2020; 20:101180. https://doi.org/10.1016/j.pmedr.2020.101180 PMID: 32953425

49. Killikelly A, Shane A, Yeung MW, Tunis M, Bancej C, House A, et al. Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat. Can Commun Dis Rep. 2020; 46(4):62–8. https://doi.org/10.14745/ccdr.v46i04a02 PMID: 32281988

50. Nascimento MS, Baggio DM, Fascina LP, do Prado C. Impact of social isolation due to COVID-19 on the seasonality of pediatric respiratory diseases. PLoS One. 2020; 15(12):e0243694. https://doi.org/10.1371/journal.pone.0243694 PMID: 33306735

51. DeLaroche AM, Rodean J, Aronson PL, Fleegler EW, Florin TA, Goyal M, et al. Pediatric Emergency Department Visits at US Children’s Hospitals During the COVID-19 Pandemic. Pediatrics. 2021; 147(4):e2020039628. https://doi.org/10.1542/peds.2020-039628 PMID: 33361360

52. Chiu SS, Cowling BJ, Peiris JSM, Chan ELY, Wong WHS, Lee KP. Effects of Nonpharmaceutical COVID-19 Interventions on Pediatric Hospitalizations for Other Respiratory Virus Infections, Hong Kong. Emerg Infect Dis. 2022; 28(1):62–8. https://doi.org/10.3201/eid2801.211099 PMID: 34932446

53. Groves HE, Papenburg J, Mehta K, Bettinger JA, Sadarangani M, Halperin SA, et al. The effect of the COVID-19 pandemic on influenza-related hospitalization, intensive care admission and mortality in children in Canada: A population-based study. Lancet Reg Health Am. 2022; 7:100132. https://doi.org/10.1016/j.lana.2021.100132 PMID: 35291567

54. Nuzhat H, Ajayi KV, Fan Q, Hotez P, Colwell B, Callaghan T, et al. Childhood immunization during the COVID-19 pandemic in Texas. Vaccine. 2021; 39(25):3333–7. https://doi.org/10.1016/j.vaccine.2021.04.050 PMID: 34020814

55. Lee DID, Vanderhout S, Aglipay M, Birken CS, Morris SK, Piché-Renaud PP, et al. Delay in childhood vaccinations during the COVID-19 pandemic. Can J Public Health. 2022; 1:1–9. https://doi.org/10.17269/s41997-021-00601-9
56. AlGhounaim M, Xiao Y, Caya C, Papenburg J. Diagnostic yield and clinical impact of routine cell culture for respiratory viruses among children with a negative multiplex RT-PCR result. J Clin Virol. 2017; 94:107–9. https://doi.org/10.1016/j.jcv.2017.07.015 PMID: 28802185

57. Renaud C, Papenburg J. Health care-associated viral respiratory tract infections due to influenza virus, respiratory syncytial virus, and other respiratory viruses. In: Leber AL, editor. Clinical Microbiology Procedures Handbook. 4th edition ed. Washington, DC: Am Soc Microbiol Pr; 2016.